Global Endobronchial Ultrasound Biopsy Market to Reach US$ 1.27 Billion by 2033 Driven by Rising Cancer Diagnostics Demand

Endobronchial Ultrasound Biopsy Market Analysis

The Endobronchial Ultrasound (EBUS) biopsy market is projected to grow steadily, reaching approximately US$ 1,275.36 million by 2033, up from US$ 820 million in 2024. This represents a compound annual growth rate (CAGR) of 5.03% during the forecast period from 2025 to 2033. Market expansion is largely driven by the rising incidence of diseases that require minimally invasive diagnostic procedures, particularly those involving endoscopic ultrasound techniques. Increasing demand for accurate and early diagnosis of conditions such as lung cancer and other respiratory disorders is further supporting market growth.

Endobronchial Ultrasound Biopsy Market Overview

The endobronchial ultrasound biopsy market is witnessing strong growth, driven by the increasing burden of lung cancer, advancements in minimally invasive diagnostic tools, and the need for precise staging and diagnosis of pulmonary diseases. EBUS has emerged as a safer and less invasive alternative to traditional surgical biopsy methods, offering faster recovery and reduced procedural risks. It is particularly effective in diagnosing and staging non-small cell lung cancer (NSCLC) and other thoracic conditions, especially in difficult-to-access or peripheral lesions. Continuous technological improvements, including enhanced imaging systems and advanced biopsy instruments, are further supporting market expansion. Leading companies such as Cook Medical, Boston Scientific, Medtronic, and Olympus Corporation are actively investing in research and product innovation to meet the rising clinical demand.

Several contributing factors are fueling this upward trend, including the growing prevalence of cancer, increasing respiratory disorders, an aging global population, and the broader adoption of minimally invasive procedures. According to global health estimates, the population aged 60 and above is expected to rise significantly, which will further increase the demand for advanced diagnostic solutions. As older populations are more susceptible to chronic diseases, the need for efficient and accurate diagnostic tools like EBUS continues to grow.

The rising incidence of lung cancer remains a key driver of the EBUS biopsy market. Factors such as smoking, environmental pollution, and occupational exposure contribute to increasing case numbers worldwide. Early and accurate diagnosis is critical for improving survival outcomes, and EBUS-guided biopsy plays a vital role by enabling precise sampling of lymph nodes and lung tissues. This technique supports early detection and accurate staging, which are essential for effective treatment planning.

In addition, the growing prevalence of respiratory diseases such as tuberculosis and chronic obstructive pulmonary disease (COPD) is further boosting demand for EBUS procedures. These conditions are becoming more widespread due to environmental and lifestyle factors, increasing the need for reliable, minimally invasive diagnostic methods. Technological advancements—such as real-time needle guidance and high-resolution imaging—are enhancing diagnostic accuracy and efficiency, encouraging wider adoption of EBUS among healthcare providers.

Request Sample Report: https://www.renub.com/request-sample-page.php?gturl=endobronchial-ultrasound-biopsy-market-p.php

New Cases and deaths of lung cancer by UN-defined world regions in 2022, both sexes.

Cancer Incidence (2,480,675 New Cases)

·       Eastern Asia — 1,243,931 cases (50.1%)

·       Northern America — 257,284 cases (10.4%)

·       Eastern Europe — 158,147 cases (6.4%)

·       Western Europe — 145,941 cases (5.9%)

·       South-Eastern Asia — 131,184 cases (5.3%)

·       South Central Asia — 129,889 cases (5.2%)

·       Others — 414,299 cases (16.7%)

Cancer Mortality (1,817,469 Deaths)

·       Eastern Asia — 851,876 deaths (46.9%)

·       Northern America — 150,675 deaths (8.3%)

·       Eastern Europe — 126,840 deaths (7.0%)

·       South Central Asia — 118,183 deaths (6.5%)

·       South-Eastern Asia — 116,366 deaths (6.4%)

·       Western Europe — 109,734 deaths (6.0%)

·       Others — 343,795 deaths (18.9%)

lung Cancer Incidence in 2019

Hungary

·       Lung cancer incidence (overall): 50.1 per 100,000

·       Lung cancer incidence (male): 66.6 per 100,000

·       Lung cancer incidence (female): 38.1 per 100,000

·       Lung cancer mortality rate: 42.4 per 100,000

·       Smoking prevalence (male): 31.5%

·       Smoking prevalence (female): 20.8%

Serbia

·       Lung cancer incidence (overall): 47.3 per 100,000

·       Lung cancer incidence (male): 68 per 100,000

·       Lung cancer incidence (female): 29.8 per 100,000

·       Lung cancer mortality rate: 40 per 100,000

·       Smoking prevalence (male): 34.1%

·       Smoking prevalence (female): 28.1%

Belgium

·       Lung cancer incidence (overall): 38.3 per 100,000

·       Lung cancer incidence (male): 52.2 per 100,000

·       Lung cancer incidence (female): 28.1 per 100,000

·       Lung cancer mortality rate: 30.5 per 100,000

·       Smoking prevalence (male): 21.6%

·       Smoking prevalence (female): 16.4%

Turkiye

·       Lung cancer incidence (overall): 40 per 100,000

·       Lung cancer incidence (male): 74.8 per 100,000

·       Lung cancer incidence (female): 9.8 per 100,000

·       Lung cancer mortality rate: 35.9 per 100,000

·       Smoking prevalence (male): 41.4%

·       Smoking prevalence (female): 16.3%

Denmark

·       Lung cancer incidence (overall): 36.8 per 100,000

·       Lung cancer incidence (male): 37.3 per 100,000

·       Lung cancer incidence (female): 36.8 per 100,000

·       Lung cancer mortality rate: 33.1 per 100,000

·       Smoking prevalence (male): 16%

·       Smoking prevalence (female): 17.3%

Poland

·       Lung cancer incidence (overall): 36.5 per 100,000

·       Lung cancer incidence (male): 52.7 per 100,000

·       Lung cancer incidence (female): 24.5 per 100,000

·       Lung cancer mortality rate: 32.8 per 100,000

·       Smoking prevalence (male): 31%

·       Smoking prevalence (female): 18%

Bosnia-Herzogovenia

·       Lung cancer incidence (overall): 37.8 per 100,000

·       Lung cancer incidence (male): 64.7 per 100,000

·       Lung cancer incidence (female): 23.5 per 100,000

·       Lung cancer mortality rate: 32.1 per 100,000

·       Smoking prevalence (male): 39.1%

·       Smoking prevalence (female): 22.6%

France

·       Lung cancer incidence (overall): 42.9 per 100,000

·       Lung cancer incidence (male): 59.9 per 100,000

·       Lung cancer incidence (female): 22.5 per 100,000

·       Lung cancer mortality rate: 31.4 per 100,000

·       Smoking prevalence (male): 32.3%

·       Smoking prevalence (female): 21.6%

China

·       Lung cancer incidence (overall): 35.1 per 100,000

·       Lung cancer incidence (male): 47.8 per 100,000

·       Lung cancer incidence (female): 22.8 per 100,000

·       Lung cancer mortality rate: 36.2 per 100,000

·       Smoking prevalence (male): 44.8%

·       Smoking prevalence (female): 2%

United States

·       Lung cancer incidence (overall): 35.1 per 100,000

·       Lung cancer incidence (male): 40.1 per 100,000

·       Lung cancer incidence (female): 30.4 per 100,000

·       Lung cancer mortality rate: 27.8 per 100,000

·       Smoking prevalence (male): 14.4%

·       Smoking prevalence (female): 11.7%

Germany

·       Lung cancer incidence (overall): 33.7 per 100,000

·       Lung cancer incidence (male): 41 per 100,000

·       Lung cancer incidence (female): 27.4 per 100,000

·       Lung cancer mortality rate: 25.8 per 100,000

·       Smoking prevalence (male): 25.1%

·       Smoking prevalence (female): 17.1%

Ireland

·       Lung cancer incidence (overall): 33.7 per 100,000

·       Lung cancer incidence (male): 38.8 per 100,000

·       Lung cancer incidence (female): 32.9 per 100,000

·       Lung cancer mortality rate: 25.9 per 100,000

·       Smoking prevalence (male): 19.9%

·       Smoking prevalence (female): 17.3%

Netherlands

·       Lung cancer incidence (overall): 33.3 per 100,000

·       Lung cancer incidence (male): 34.5 per 100,000

·       Lung cancer incidence (female): 33.5 per 100,000

·       Lung cancer mortality rate: 32.6 per 100,000

·       Smoking prevalence (male): 17%

·       Smoking prevalence (female): 17%

United Kingdom and Northern Ireland

·       Lung cancer incidence (overall): 32.5 per 100,000

·       Lung cancer incidence (male): 35.5 per 100,000

·       Lung cancer incidence (female): 29.9 per 100,000

·       Lung cancer mortality rate: 26.7 per 100,000

·       Smoking prevalence (male): 35.5%

·       Smoking prevalence (female): 30.2%

Growth Drivers for the Endobronchial Ultrasound Biopsy Market

Rising Incidence of Lung Cancer

The increasing global burden of lung cancer, particularly non-small cell lung cancer (NSCLC), is a major factor driving the demand for endobronchial ultrasound (EBUS) biopsy procedures. As one of the leading causes of cancer-related mortality, lung cancer requires timely and accurate diagnosis for effective treatment. EBUS-guided biopsy offers a minimally invasive and highly precise method for sampling lung tissues and lymph nodes, enabling early detection and accurate staging. This is essential for selecting appropriate therapies and improving patient survival rates. With the number of lung cancer cases continuing to rise due to factors such as smoking and environmental pollution, the reliance on advanced diagnostic tools like EBUS is growing significantly, thereby accelerating market expansion.

Shift Toward Minimally Invasive Procedures

The healthcare industry is increasingly moving toward minimally invasive diagnostic and treatment approaches, which is boosting the adoption of EBUS biopsy. Traditional surgical biopsy methods are often associated with higher risks, longer hospital stays, and extended recovery periods. In contrast, EBUS provides real-time imaging guidance, allowing clinicians to perform precise biopsies with reduced discomfort and fewer complications. Patients benefit from quicker recovery times and lower procedural risks, making EBUS a preferred option for diagnosing and staging lung and thoracic diseases. As healthcare systems aim to improve patient outcomes while reducing costs and hospital burdens, the preference for minimally invasive technologies like EBUS continues to strengthen, supporting sustained market growth.

Increasing Adoption in Emerging Markets

Emerging economies are witnessing a growing adoption of EBUS biopsy technologies, contributing significantly to market development. Improvements in healthcare infrastructure, along with increased investments in modern medical equipment, are enabling hospitals and diagnostic centers to incorporate advanced tools such as EBUS systems. Government initiatives aimed at expanding access to quality healthcare and enhancing diagnostic capabilities are further supporting this trend. Additionally, rising awareness about lung cancer and the importance of early diagnosis is encouraging both healthcare providers and patients to opt for accurate and less invasive diagnostic solutions. As cancer incidence rises in these regions, the demand for efficient diagnostic techniques continues to increase, positioning EBUS as a key tool in modern respiratory care and driving market growth globally.

Ask Analyst for Customization in Report:https://www.renub.com/request-sample-page.php?gturl=endobronchial-ultrasound-biopsy-market-p.php

Country Analysis

United States Endobronchial Ultrasound Biopsy Market

The United States endobronchial ultrasound (EBUS) biopsy market is experiencing strong growth, driven by the rising prevalence of lung cancer and the increasing preference for minimally invasive diagnostic procedures. EBUS provides a highly accurate and less invasive alternative to conventional biopsy techniques, enabling effective diagnosis and staging of lung cancer and other pulmonary conditions. Its ability to access difficult-to-reach lesions and deliver real-time imaging guidance makes it an essential tool for clinicians in treatment planning. Continuous advancements in ultrasound technology, along with growing physician adoption, are further supporting market expansion. Backed by a well-established healthcare infrastructure, advanced medical innovation, and a supportive regulatory environment, the U.S. continues to lead the global EBUS biopsy market. The increasing burden of lung cancer remains a key factor accelerating demand for EBUS procedures. Rising cancer incidence rates are expected to further boost market growth, with lung and bronchus cancers contributing a significant share of total cases. EBUS offers a safer and more efficient approach to obtaining tissue samples compared to traditional surgical biopsies. Since the procedure can be performed under local anesthesia with moderate sedation, it is widely preferred for its reduced risk and faster recovery. As the number of lung cancer patients continues to grow, the demand for EBUS-based diagnostics is expected to rise steadily.

United Kingdom Endobronchial Ultrasound Biopsy Market

The United Kingdom EBUS biopsy market is growing steadily, supported by the increasing incidence of lung diseases and a rising demand for less invasive diagnostic solutions. EBUS is widely recognized as an effective alternative to traditional biopsy methods, offering precise staging and diagnosis of pulmonary disorders. The country’s strong healthcare system, favorable reimbursement structure, and focus on adopting advanced diagnostic technologies contribute to market growth. However, factors such as high equipment costs and the need for specialized training may limit widespread adoption in certain regions. Despite these challenges, ongoing technological advancements and increasing awareness are expected to drive continued expansion of the EBUS market in the UK.

India Endobronchial Ultrasound Biopsy Market

India’s EBUS biopsy market is expanding rapidly due to the growing incidence of respiratory diseases and improvements in diagnostic capabilities. Increasing awareness of minimally invasive procedures and expanding healthcare infrastructure are encouraging the adoption of EBUS in hospitals and specialty clinics. The technology is becoming an important tool for accurate diagnosis and staging of lung cancer and other pulmonary disorders. Government initiatives aimed at strengthening healthcare access and quality are further supporting the use of advanced diagnostic solutions. However, challenges such as high equipment costs and the requirement for trained professionals may restrict adoption in certain regions. Despite this, the market holds strong growth potential in the coming years.

Saudi Arabia Endobronchial Ultrasound Biopsy Market

The Saudi Arabia EBUS biopsy market is witnessing steady growth, driven by the increasing prevalence of lung diseases and ongoing advancements in diagnostic technologies. Expanding healthcare infrastructure and growing awareness of minimally invasive procedures are supporting the adoption of EBUS in clinical settings. Hospitals and specialized medical centers are increasingly utilizing this technology for accurate diagnosis and staging of lung cancer and other respiratory conditions. Government initiatives focused on improving healthcare services and access to advanced technologies are further boosting market development. However, factors such as high equipment costs and the need for specialized training may pose challenges to widespread adoption. Overall, the market is expected to grow as healthcare modernization efforts continue across the country.

Market Segmentation

Product

·       EBUS Scopes

·       EBUS Needles

·       Ultrasound Processors and Imaging Systems

·       Accessories

Application

·       Cancer Diagnostic

·       Infection Diagnostic

·       Others

End Use

·       Hospitals

·       Ambulatory Surgical Centers (ASCs)

·       Specialty Clinics    

Country

North America

·       United States

·       Canada

Europe

·       France

·       Germany

·       Italy

·       Spain

·       United Kingdom

·       Belgium

·       Netherlands

·       Turkey

Asia Pacific

·       China

·       Japan

·       India

·       Australia

·       South Korea

·       Thailand

·       Malaysia

·       Indonesia

·       New Zealand

Latin America

·       Brazil

·       Mexico

·       Argentina

Middle East & Africa

·       South Africa

·       Saudi Arabia

·       United Arab Emirates

All the Key players have been covered from 5 Viewpoints:

·       Overview

·       Key Persons

·       Recent Development & Strategies

·       Revenue Analysis

Company Analysis:

·       GE Healthcare

·       Siemens Healthcare Private Limited

·       Koninklijke Philips N.V.

·       Boston Scientific Corporation

·       Olympus Corporation

·       Cook Group Incorporated

·       FUJIFILM Holdings Corporation

·       Medi-Globe Technologies GmbH

About the Company:

Renub Research is a Market Research and Consulting Company. We have more than 15 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food Beverages, Power Energy, Information Technology, Telecom Internet, Chemical, Logistics Automotive, Consumer Goods Retail, Building, and Construction, Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more.   

Contact Us:

Company Name: Renub Research

Contact Person: Rajat Gupta

Phone No: (D) +91-120-421-9822 (IND)

Website: https://www.renub.com/

Email: rajat@renub.com